F. Stephen Hodi

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy

Hussein Tawbi, Aliya N. Husain, L. Heinzerling, 2016, Journal of Immunotherapy for Cancer.

Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.

Jedd D. Wolchok, Antoni Ribas, Richard F. Kefford, 2016 .

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

Shohei Koyama, Robert E. Jones, Gordon J. Freeman, 2016, Nature Communications.

Improved Endpoints for Cancer Immunotherapy Trials

Sylvia Janetzki, Axel Hoos, J. Wolchok, 2010, Journal of the National Cancer Institute.

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

Suzanne F. Jones, Fabien Gaire, P. Hegde, 2016, Nature Communications.

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

Axel Hoos, Jedd D. Wolchok, J. Wolchok, 2009, Clinical Cancer Research.